Double Your Impact

Gifts made by Midnight on December 31, 2019 will be matched dollar for dollar!

Clinical trials are critical to scientific breakthroughs and hold the promise of increasing patients’ quality of life, improving outcomes, and giving patients and their families more time together. Lustgarten-funded trials could one day lead to new treatment options and a potential cure for patients like Charlie, a patient who has undergone surgery and other treatments.


Pancreatic cancer

6 Things to Know About a Pancreatic Cancer Diagnosis

Have you or has a loved one had a pancreatic cancer diagnosis? It’s estimated that more than 56,000 Americans will be diagnosed this year alone, and the five-year survival rate remains in the single digits.

The Lustgarten Foundation is the world’s largest private funder of pancreatic cancer research and is at the forefront of the most promising breakthroughs. The Foundation is committed to helping you navigate this disease and has developed a checklist that highlights immediate steps you or your loved ones should take after receiving this diagnosis.

Understand your disease

Thoroughly understand what stage of pancreatic cancer you have. Staging cancer is a standardized way to classify a tumor based on its size,  and to determine whether it has spread and to where it has spread. Staging measures the extent of the disease and will impact the treatment plan.

Get genetic testing as part of a pancreatic cancer diagnosis

Inquire about having your blood or saliva tested to identify possible genetic predispositions to cancer. This testing can have implications for family members and can guide your treatment program.

According to the National Comprehensive Cancer Network’s guidelines, all pancreatic cancer patients should undergo genetic testing for inherited genetic mutations, regardless of family history.

Get tumor testing

Tumor testing is still in the early stages of development, but if you are being treated at a major cancer center, you may want to ask about having your tumor tested for genetic mutations. In some instances, this can help identify additional therapy programs.

Seek opinions from experts on pancreatic cancer

Get two opinions and make sure one is from a large academic institution that specializes in treating pancreatic cancer.

Know your healthcare team

Treating pancreatic cancer requires an interdisciplinary approach that includes your oncologist and other specialists who must be involved in your care. Continue to see other doctors who are involved in your overall care, such as your internist.

Contact your insurance company

Thoroughly understand your health insurance policy. Know what services are covered and what your out-of-pocket obligation will be per calendar year. Request a case manager to help you optimize your benefits and navigate the intricacies of your policy.

As overwhelming as a pancreatic cancer diagnosis can be, it is important to act quickly and put a treatment plan into place, as there are therapies available from which you can benefit.

For more information, view our complete checklist for newly diagnosed patients. To learn more about the Lustgarten Foundation’s research program, as well as treatment options and patient resources, visit the Lustgarten Foundation or call 866.789.1000.

Make a difference in patients’ lives by donating to the Lustgarten Foundation today and supporting pancreatic cancer research. We couldn’t accomplish all that we do without you!

Interview with an Expert: Familial Pancreatic Cancer

Our Familial Pancreatic Cancer Expert: Ralph Hruban, M.D., is Professor of Pathology and Oncology, and Director of the Sol Goldman Pancreatic Cancer Research Center at the Johns Hopkins University School of Medicine in Baltimore, MD. Dr. Hruban founded the National Familial Pancreas Tumor Registry (NFPTR) and helped define the clustering of pancreatic cancer in families as well as discover new familial pancreatic cancer genes (PALB2 and ATM). These discoveries now guide genetic counseling.

“I believe that just as there is a colonoscopy available to test for early curable colon cancer, we need an early detection test for pancreatic cancer.”

Q: Is the chance of getting pancreatic cancer increased if someone has a family member with pancreatic cancer?

The risk of developing pancreatic cancer does increase when someone has a family member with the disease. In fact, approximately 10 percent of pancreatic cancer cases are attributed to genetic causes. The risk increases with the number of first-degree relatives (i.e., a sibling, parent, or child) that someone has who have been diagnosed with pancreatic cancer.

Q: How much does the chance of getting pancreatic cancer change from having one first-degree relative with the disease, to two first-degree relatives, etc.?

One first-degree relative confers a two-fold to four-fold risk, two relatives increases the risk by six-fold or seven-fold, and three first-degree relatives, which is highly unusual, results in a 32-fold risk. A family member who had a young age of onset of pancreatic cancer (younger than 50) confers an added risk of pancreatic cancer.

It is important to realize that despite these increased risks when pancreatic cancer runs in families, the disease strikes only nine people per 100,000 each year. Even in the older population, comprised of people over 55 years old, the risk is still only 68 people per 100,000 in the United States.

Q: The genomes of over 600 people with familial pancreatic cancer were recently sequenced. What was learned from this study? Do you believe there are still other unidentified genetic mutations responsible for pancreatic cancer that we have yet to discover?

This study is a wonderful example of how pancreatic cancer researchers pull together and collaborate to advance our knowledge of this devastating disease. The study included investigators from Johns Hopkins University, Mayo Clinic, Baylor University, Dana-Farber Cancer Institute, University of Pittsburgh, Memorial Sloan Kettering Cancer Center, University of Pennsylvania, Wayne State University, University of Michigan, and McGill University and Mount Sinai Hospital in Canada. The study involved the sequencing of DNA in the blood of 600 people who themselves had pancreatic cancer or had a very strong family history of pancreatic cancer. The study furthered what is known about familial pancreatic cancer by producing four key findings:

  1. The findings confirmed many of the genes that were known before the study such as BRCA2, CDKN2A (the p16 gene), ATM (which plays a role in the processes that repair DNA double-strand breaks), and other genes that are linked to familial pancreatic cancer.
  2. The research helped identify some novel candidates that could also be additional familial pancreatic cancer genes, such as BUB1B, which is involved in cell division.
  3. The study revealed that familial pancreatic cancer is not one disease. There appear to be several different genes that explain familial pancreatic cancer, rather than just one gene. The 600 study participants didn’t have one genetic mutation that explained all 600 families.

Instead, the research demonstrated that one family had one mutation, another family had a different gene targeted, and the third family had yet another different gene targeted.

  1. Some people who develop familial pancreatic cancer have two genetic defects. They inherited two different genes that predispose them to developing pancreatic cancer.

This research, led by principal investigator Dr. Nick Roberts and made available to other scientists, demonstrates how exciting advances can be made in the study of pancreatic cancer when researchers from across institutions join together and are united by their common purpose of fighting this disease.

Q: What are the specific genes responsible for familial pancreatic cancer, and are these genes different from the genes responsible for sporadic (noninherited) pancreatic cancer?

There are several genes that have been identified that when inherited in an abnormal form, increase the risk of developing pancreatic cancer, including the breast cancer genes BRCA1, BRCA2, and PALB2. An abnormal copy of the BRCA2 gene confers a three-fold to 10-fold increased risk, resulting in a lifetime risk of pancreatic cancer in carriers of this mutation as high as 10 percent. The PALB2 gene’s official name is “partner and localizer of BRCA2,” and this gene works with the BRCA2 gene to repair damaged DNA. It is now known that approximately three percent of patients with familial pancreatic cancer have inherited mutations in this gene, and mutations in this gene have also been associated with an increased risk of breast cancer.

When the CDKN2A/p16 gene is inherited in an abnormal form, it can cause familial pancreatic cancer and melanoma, and the increased lifetime risk of pancreatic cancer is 15-35 percent. Mutations in this gene are rare and are believed to account for three percent of familial pancreatic cancer cases.

There is another gene called the Peutz-Jeghers gene or STK11, and individuals who inherit an abnormal copy of this gene have a 130-fold increased risk of developing pancreatic cancer, amounting to approximately 35 percent by age 60. However, mutations in this gene are rare and account for less than one percent of familial pancreatic cancer cases. There is also a class of genes called the mismatch repair genes that cause a type of hereditary colorectal cancer, and individuals with those genes have an eight-fold increased risk of getting pancreatic cancer, amounting to a four percent lifetime risk. Additionally, the PRSS1 gene, which is the familial pancreatitis gene, confers a 50-fold to 80-fold increased risk of developing pancreatic cancer, amounting to a 25-40 percent lifetime risk.

What is so critical about these genes is that when we know the gene that causes pancreatic cancer to run in a family, we can calculate the risk that the carriers of that genetic defect have for developing pancreatic cancer. Moreover, almost all these inherited genes, except for the pancreatitis gene, raise the risk of additional cancers outside of the pancreas, and these cancers can also be screened for, potentially saving lives.

For many of these genes, there are targeted therapy options available. For instance, when someone with a BRCA2 mutation develops pancreatic cancer, the doctor can prescribe a specific targeted cancer therapy such as a PARP inhibitor.

Understanding the genes that cause familial pancreatic cancer is critically important. It helps us quantify the risk of pancreatic cancer and the risk of cancers outside of the pancreas, and we can save lives by monitoring and detecting these cancers when they are at a very early, potentially curable state.

Q: Besides the genes you’ve just identified, are there environmental factors or health risks that could cause pancreatic cancer?

Cigarette smoking is the leading preventable cause of pancreatic cancer, and if we could get people to quit smoking, we could save lives by reducing pancreatic cancer as well as other cancers. Obesity has been associated with an increased risk of pancreatic cancer, so I urge people to eat a well-balanced diet, maintain a healthy body weight, and get regular exercise. There are also several studies that diets high in red meats, particularly barbecued red meats and smoked red meats, increase the risk of cancers including pancreatic cancer.

Q: If someone thought he or she might be at risk for developing pancreatic cancer because of a family history or a specific risk factor, what advice would you give?

There are proactive measures people can take to reduce their risk, including maintaining a healthy body weight and not smoking. Additionally, if there is a significant family history of breast cancer in the family, as well as pancreatic cancer, there is genetic testing available for the breast cancer genes BRCA1, BRCA2, and PALB2. If there is a strong family history of melanoma in addition to pancreatic cancer, there is genetic testing available for the p16 or CDKN2A gene. If this strong family history exists, one immediate next step is to speak to a cancer genetic counselor who can advise patients on the benefits and risks of genetic testing. The genetic counselor will go over the family history, ascertain if there appears to be a hereditary component, and try to determine a person’s lifetime risk for pancreatic cancer. Moreover, some people may choose to participate in familial pancreatic cancer research registries at leading institutions across the United States.

Q: Some people without any known risk factors for developing pancreatic cancer develop the disease, while other people with risk factors such as a strong family history of pancreatic cancer never develop pancreatic cancer. Please explain how this could be possible.

There are three reasons that people develop cancer. The first is that they inherit a genetic defect that predisposes them to develop the disease, such as breast cancer genes increasing the risk of pancreatic cancer. The second is that people can damage their DNA due to environmental factors. For example, if someone is smoking cigarettes, the carcinogens they inhale can enter the bloodstream and damage a cell in the pancreas, potentially causing pancreatic cancer. The third reason that people develop pancreatic cancer is due to chance. We have trillions of cells in our bodies, and the cells are constantly dividing. Every time a cell divides, it must copy all six billion base pairs of DNA in the cell. Mistakes get made during this process. If a mistake is made in copying DNA in a pancreas cell and it affects a cancer gene, someone may develop pancreatic cancer.

Inheritance accounts for approximately 10 percent of pancreatic cancer cases; environmental factors such as smoking and obesity are estimated to cause between 20-30 percent of pancreatic cancer cases; and the remaining 60-70 percent of cases are due to chance.

“Our knowledge of familial pancreatic cancer is a wonderful example of the power of physicians, patients and scientists collaborating to understand this disease. I’m confident that working together, we can move forward and start to save lives through early detection and other approaches.”

Q: Is there a universal clinically validated screening process? How can patients determine where they should go to receive screening that is best for them?

There currently isn’t a clinically validated screening process, although significant strides are being made in this area. Most cases of pancreatic cancer are unfortunately not detected until the disease has reached an advanced stage, where patients are no longer candidates for surgery and other potentially curable approaches. In fact, pancreatic cancer is often labeled a silent disease because many times the signs and symptoms can go unnoticed until the cancer is in the advanced stage.

If we can detect the disease earlier, then we can save more lives. There are multiple studies ongoing using techniques such as endoscopic ultrasound, including the Cancer of the Pancreas Screening (CAPS) study being conducted by my colleague Dr. Marcia Canto at Johns Hopkins University. As part of the CAPS study, at-risk family members are screened using endoscopic ultrasound for precancerous lesions and early cancers in their pancreas. In addition to Johns Hopkins, the CAPS study is taking place at Case Comprehensive Cancer Center; Columbia University Medical Center; Dana-Farber Cancer Institute; University of Michigan; University of Pennsylvania; University of Pittsburgh; and Yale University.

My colleague Dr. Bert Vogelstein, also at Johns Hopkins, is working on a blood test called CancerSEEK that can detect the early presence of pancreatic cancer as part of a panel of eight common cancers and identify where the cancer originated in the body. The FDA recently granted “Fast Track” status for the pancreatic and ovarian cancer portions of CancerSEEK, accelerating the approval process of this important blood test.  Dr. Vogelstein and his team continue to improve the sensitivity of this test so that it can become the first blood test used routinely, like the PSA test for prostate cancer. The Lustgarten Foundation is supporting this research.

Dr. Vogelstein and his team also developed a Comprehensive Cyst (CompCyst) test, which combines clinical, radiological, genetic and protein marker information to distinguish if pancreatic cysts, which can be common amongst the general population, can develop into pancreatic cancer or remain as benign cysts. They are working to further develop the CompCyst test into a clinically approved test for many people harboring pancreatic cysts. This research to determine which cysts require surgery and which require surveillance only is critical so that difficult surgery could be avoided in patients with benign cysts, while patients with potentially malignant cysts (approximately 20 percent) could benefit from early surgical intervention.

Additionally, my research has shown that small precursor lesions in the pancreas can give rise to pancreatic cancer. I believe that just as there is a colonoscopy available to test for early curable colon cancer, we need an early detection test for pancreatic cancer.

Q: What is the National Familial Pancreas Tumor Registry (NFPTR)?

We founded the NFPTR in 1994 at Johns Hopkins University. It is the first familial pancreas tumor registry in the country and is the longest standing and one of the largest familial pancreatic cancer registries in the world, attracting international participants as well. There have been more than 7,200 families enrolled in this registry, and the participants have been part of several different studies that have helped identify and quantify the risk of pancreatic cancer in relatives. We’ve helped identify pancreatic cancer genes, the other tumor types that are associated with pancreatic cancer, and the pathology changes in the pancreas that occur in people with a strong family history of the disease. The research that has emerged through this registry has helped to significantly advance our understanding of familial pancreatic cancer. In fact, using the registry, we’ve produced more than 50 peer-reviewed publications, and we work with a team of clinicians and scientists with backgrounds and training in areas such as epidemiology, pathology, gastroenterology, genetics, radiology, and oncology.

Q: What do you do with the information you collect from the family registry?

When individuals join the registry, they answer a detailed personal family history and personal exposure history questionnaire, including questions such as whether the person who developed pancreatic cancer was a smoker and if this person has a family history of other types of cancers such as melanoma or breast cancer. We then use this information to determine patterns of inheritance and calculate risk, using a sophisticated computer model called PancPRO developed by Dr. Alison Klein, Director of the NFPTR at Johns Hopkins University. The PancPRO model is now available to genetic counselors across the country so that they can help family members calculate their risk of getting pancreatic cancer. Using the registry, we’ve been able to show that in women, having a family member with pancreatic cancer increases the risk of developing breast cancer and ovarian cancer. We can also compare the importance of gene-environment interactions. For example, smokers who have relatives with pancreatic cancer are at an increased risk due to both heredity and cigarette use.

Q: At what age would you recommend screening and/or participation in a familial pancreatic cancer registry?

Any adult 18 years or older can participate in a familial pancreatic cancer registry. While there isn’t currently a clinically validated screening test, participating in research studies like the National Familial Pancreas Tumor Registry can help advance the field.

Q: Are there any costs incurred to an individual who wants to become part of a registry?

No, individuals who join a registry do not incur costs. The costs are usually taken care of by the registry, from mailing costs to blood-drawing and blood-shipping costs. Individuals can sign up for the registries online.

Q: Who would you encourage to participate in the registry? For example, if someone has only one family member who currently has or previously had pancreatic cancer, would you encourage him or her to join the registry?

I would encourage anyone with even one family member with pancreatic cancer, and anyone who is a pancreatic cancer patient, to join the registry. With each person who joins the registry, there is new information that could help us with potential new discoveries.

Q: How could a family register, and what are the next steps once a family registers?

People interested in joining the registry can email us at, or register online through our website,

Q: What other groups do you collaborate with? What is PACGENE’s role in working with people who have a family history of pancreatic cancer?

As I mentioned earlier, we partnered with several other major familial pancreatic cancer research centers to study the DNA of 600 people with familial pancreatic cancer. Johns Hopkins University is also very involved in a consortium called PACGENE (Pancreatic Cancer Genetic Epidemiology), founded by Gloria M. Petersen, Ph.D., at the Mayo Clinic, and originally funded by the National Cancer Institute, to collaborate in the search for familial pancreatic cancer genes. This group worked together on a paper in which samples from multiple centers were pooled and analyzed to determine which of the known genes cause familial pancreatic cancer. Research demonstrated that the BRAC2 and p16 genes are the most common causes of familial pancreatic cancer.

Q: Are there any new studies or advances regarding screening tests and early detection tests?

Screening and early detection are two very promising research areas. As new genes are identified that predispose people to pancreatic cancer, we can quantify the risk, and we can offer these individuals options including endoscopic ultrasound (EUS), which is a minimally invasive procedure using high-frequency sound waves to create detailed images of the lining and walls of the digestive tract and organs such as the pancreas and liver, and lymph nodes.

There are also many novel DNA-based techniques. They range from analyzing circulating tumor DNA, which gives researchers and physicians insights about cancer mutations and how they react to treatment, to sequencing pancreatic secretions/pancreatic juices at the time of endoscopy. We also know what the pre-cancerous lesions and pancreatic cysts look like. Just as we know a colon polyp can lead to colon cancer, we know that there is a window of opportunity to detect precancerous lesions in the pancreas before they become cancerous, as well as early stage pancreatic tumors, so they can be treated before they lead to metastatic pancreatic cancer. Through monitoring of family members who have loved ones with pancreatic cancer, I am confident that our research will significantly change the future of pancreatic cancer.

Make a difference in patients’ lives by donating to the Lustgarten Foundation today and supporting pancreatic cancer research. We couldn’t accomplish all that we do without you.

Interview with an Expert: Immunotherapy Update

About Our Expert: Elizabeth M. Jaffee, M.D., is an internationally recognized expert in pancreatic cancer and immunotherapy research. She is the Deputy Director at the Sidney Kimmel Cancer Center at Johns Hopkins and an Associate Director of the Bloomberg-Kimmel Institute for Immunotherapy. Dr. Jaffee serves as the Chief Medical Advisor for the Lustgarten Foundation as well.

Immunotherapy is touted as the pancreatic cancer treatment option of the future. It involves using a person’s own immune system to fight and destroy cancer cells and is considered by many leading researchers to represent a new and promising direction for cancer treatment. While immunotherapy has been successful in treating other diseases, only recently have we made breakthroughs in applying immunotherapy to pancreatic cancer treatment. Significant research involving immunotherapies is paving the way toward more promising pancreatic cancer treatment options for patients, although much more work needs to be done in this area.

How does cancer immunotherapy treatment options work?

Immunotherapy is a form of treatment in which we harness the immune system, which is meant to keep us healthy and fight infections and diseases. Cancer immunotherapy works similarly. The immune system is designed to recognize germs and viruses as invaders and get rid of these invaders so we remain healthy. Cancerous cells are invaders and can evade our immune system. Sometimes there are so many that the immune system becomes overwhelmed, and sometimes cancerous cells give off substances that stop the immune system from doing its job.

The goal of cancer immunotherapy is to help the immune system fight these cancerous cells. One way the immune system fights these cells is through the use of monoclonal antibodies, which are man-made antibodies or proteins that will target and destroy a specific part of a cancer cell. We can also use drugs like checkpoint inhibitors to give a boost to the immune system by “taking off the immune system brakes.” Once those brakes are off, the immune system can better recognize and then attack cancerous cells.

Another immunotherapy option involves the use of therapeutic vaccines, meaning they are designed to treat a disease, such as cancer, that’s already present. Doctors are also using patients’ own immune cells to treat their cancer, through a process called adoptive T-cell transfer. This approach has been tested in several clinical trials, resulting in significant responses for patients with advanced blood cancers. Trials are underway for solid tumors like pancreatic cancer.

How has our understanding of the immune system’s response to cancer changed?

There have been incredible strides made over the last 30 years in our understanding of cancer and the immune response. Today, through ongoing scientific research, we better understand the genetic drivers behind potentially life-threatening cancers. Technology has changed dramatically, especially molecular technology. We now have faster and less expensive genetic sequencing, and that means we can use treatments targeting the mutation that’s driving the cancer. We now know that pancreatic cancer has a minimal natural immune response.

However, I am confident that we will see progress in pancreatic cancer and other cancers that don’t naturally respond well to immunotherapy, and that’s due to a better understanding of the immune system. Mouse models are also helping to show inhibitory pathways within the pancreatic tumor microenvironment that prevent immunotherapy from working. We hope these models will provide valuable information that will lead to new immunotherapeutic opportunities.

Is immunotherapy treatment right for everyone?

We know that cancers with more mutations typically respond better to certain immunotherapy drugs. There have also been incredible stories of patients being cured of a particular cancer and stories of others who maybe only had a few months to live, gaining years through immunotherapy treatment. Despite these stories, immunotherapy only works for some patients, and researchers are trying to find out why. We know that immunotherapy is a powerful tool, but we still don’t fully understand it and we still can’t fully control it, so it is not right for everybody.

Patients who undergo immunotherapy treatment receive scans and other tests at intervals that are dependent upon the treatment protocol. More research is needed to determine how long a patient can stay on immunotherapy, and this research can vary, as every immunotherapy is different.

Are there any FDA-approved immunotherapy treatments available for pancreatic cancer patients?

The FDA approved pembrolizumab (Keytruda®) as the first immunotherapy treatment for advanced pancreatic cancer patients whose tumors have a unique genetic mutation called mismatch repair deficiency, which alters their capacity to repair DNA and is a factor in cancer development. Approximately 1-2% of pancreatic cancer patients have tumors with this mutation. To put that in perspective, an average cancer cell has approximately 70 mutations, while a mismatch repair deficient cell has about 1,700 mutations.

The Lustgarten Foundation supported this research on pembrolizumab, encouraged patients to get tested, and funded patients’ testing to determine if their tumors are mismatch repair deficient.

The Lustgarten Foundation envisions a world in which pancreatic cancer is curable and patients will be treated effectively through immunotherapy and other treatment options and enjoy a good quality of life. Find out more about our work as the world’s largest private funder of pancreatic cancer research.


Double Your Donation!

Imagine a world with a cure for pancreatic cancer.

Now imagine you have the power to make that dream a reality — because you do!
Thanks to a generous $175,000 match, it’s easier than ever to make a difference on #GIVINGTUESDAY.

“Extraordinary responders” could hold clues to helping others with pancreatic cancer

It’s estimated that more than 56,000 Americans will be diagnosed with pancreatic cancer this year and nearly 46,000 will die from it. Supreme Court Justice Ruth Bader Ginsburg and “Jeopardy!” host Alex Trebek are two well-known patients who have fought it.

But a group of patients, who are not celebrities, could help change the future of treatment for others.

Three years ago, Arnold Simon’s doctor told him he had “advanced” pancreatic cancer that had spread to his liver.

ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase in Metastatic Pancreatic Cancer in the European Journal of Cancer

ERYTECH Pharma (Nasdaq and Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that the full results from its Phase 2b trial evaluating eryaspase in metastatic pancreatic cancer are now published online in the European Journal of Cancer.

The Phase 2b trial evaluated eryaspase, L-asparaginase encapsulated in red blood cells, as a second-line treatment in combination with chemotherapy in 141 patients with metastatic pancreatic cancer. In this trial, conducted in France, eryaspase was added to gemcitabine or mFOLFOX chemotherapy and compared to the chemotherapy alone in a 2-to-1 randomization.

Eryaspase in combination with chemotherapy significantly prolonged both Overall Survival (OS) and Progression Free Survival (PFS) in the entire patient population, with a 40% reduction in the risk of death (OS HR, 0.60; P=0.008), and a 44% reduction in risk of disease progression on average over time (PFS HR, 0.56; P=0.005). No unexpected safety findings were reported and eryaspase did not add substantially to the toxicity of chemotherapy. The results of the trial were first presented at ESMO 20171.

‘Magic bullet’ takes aim at pancreatic cancer

Every day, more than 1200 people worldwide are told they have pancreatic cancer. Within 12 months, 80 per cent of them will have succumbed to the disease.

It’s one of the most lethal cancers in the world but new research from the University of South Australia could help vastly improve the prognosis for pancreatic cancer patients. Using a new targeted radioimmunotherapy agent, UniSA Professor of Medical Radiation Science, Eva Bezak, hopes to more accurately target and kill pancreatic cancer cells. Prof Bezak is leading a team of researchers, including PhD student Ashleigh Hull and molecular biologist Dr Judy Li,  who are combining a targeting protein and a radioisotope, known as actinium-225, to create a radioimmunoconjugate capable of treating cancer.

Pancreatic cancer tumor classification could optimize treatment choices

CHAPEL HILL — A study from the University of North Carolina Lineberger Comprehensive Cancer Center could help predict resistance to treatments for pancreatic cancer, one of the deadliest cancer types.

In Clinical Cancer Research, a journal of the American Association for Cancer Research, researchers led by UNC Lineberger’s Jen Jen Yeh, MD, and Naim Rashid, PhD, reported findings for how two subtypes of pancreatic cancer respond to treatments differently. Importantly, they found that one subtype of the disease showed poor responses to common therapies and also had worse survival.

Pancreatic Cancer Survivor Nick Pifani Believes Genetic Testing Helped Him Beat the Odds

Now cancer-free for two years, Nick Pifani wants to raise awareness, money — and hope November 21 marks World Pancreatic Cancer Day, a reminder that the disease that took the lives of Steve Jobs and Patrick Swayze — and is currently being battled by Jeopardy! host Alex Trebek — still has an abysmally low survival rate of just 9 percent. However, two-year survivor Nick Pifani, 44, wants other patients currently facing pancreatic cancer to remember that it’s not always a death sentence, and that patient knowledge, advocacy and genetic testing is pivotal when it comes to beating the odds.

Get Involved Today

Get inspired and connect with patients, survivors and loved ones who are all on the same journey.

Back to Top